{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:29:37Z","timestamp":1794324577910,"version":"4.9.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002063.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T00:00:00Z","timestamp":1411084800000}}],"reference-count":88,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002063.pub6","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T10:39:52Z","timestamp":1411123192000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome"],"prefix":"10.1002","volume":"2019","author":[{"given":"Richard AC","family":"Hughes","sequence":"first","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; MRC Centre for Neuromuscular Diseases; PO Box 114 Queen Square London UK WC1N 3BG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V","family":"Swan","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; Cochrane Neuromuscular Disease Group, MRC Centre for Neuromuscular Diseases; PO Box 114 London UK WC1N 3BG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center; Department of Neurology; PO Box 2040 Rotterdam Netherlands 3000 CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune absorption in Guillain-Barr\u00e9 syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"European Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Critical Care (London, England)"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00365549509019016","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barr\u00e9 syndrome","volume":"27","author":"G\u00fcrses","year":"1995","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1526-0968.2000.00182.x","article-title":"Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barr\u00e9 syndrome","volume":"4","author":"Haupt","year":"2000","journal-title":"Therapeutic Apheresis"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0022-510X(95)00357-8","article-title":"Sequential treatment of Guillain-Barr\u00e9 syndrome with extracorporeal elimination and intravenous immunoglobulin","volume":"137","author":"Haupt","year":"1996","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-9987.1997.tb00014.x","article-title":"Sequential treatment of Guillain-Barr\u00e9 syndrome with extracorporeal elimination and intravenous immunoglobulin","volume":"1","author":"Haupt","year":"1997","journal-title":"Therapeutic Apheresis"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00e9 syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0009|cit9","first-page":"724","article-title":"Prospective multicentre study on treatment of Guillain-Barr\u00e9 syndrome with high-dose immunoglobulins","volume":"12","author":"Korinthenberg","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00e9 syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0011|cit11","first-page":"724","article-title":"Prospective multicentre study on treatment of Guillain-Barr\u00e9 syndrome with high-dose immunoglobulins","volume":"12","author":"Korinthenberg","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0012|cit12","first-page":"69","article-title":"A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barr\u00e9 syndrome","volume":"18","author":"Nomura","year":"2001","journal-title":"Neurological Therapeutics"},{"issue":"9047","key":"10.1002\/14651858.CD002063.pub6-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","author":"PSGBS Study Group","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0015|cit14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002063.pub6-BIB0014|cit15","first-page":"135s","article-title":"Comparison of two doses of immunoglobulin for patients with GBS and contraindications to plasma exchange","volume":"7","author":"Rapha\u00ebl","year":"1998","journal-title":"R\u00e9animation Urgences"},{"issue":"17","key":"10.1002\/14651858.CD002063.pub6-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"326","author":"Mech\u00e9","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0017|cit17","first-page":"223","article-title":"Intravenous immunoglobulin therapy in children with Guillain-Barr\u00e9 syndrome","volume":"16","author":"Wang","year":"2001","journal-title":"Journal of Applied Clinical Pediatrics"},{"issue":"4-6","key":"10.1002\/14651858.CD002063.pub6-BIB0018|cit18","first-page":"369","article-title":"Plasma exchange and IV immunoglobulins: new approaches to the treatment of Guillain-Barr\u00e9 syndrome","volume":"47","author":"Fasanaro","year":"1992","journal-title":"Acta Neurologica (Napoli)"},{"issue":"5","key":"10.1002\/14651858.CD002063.pub6-BIB0019|cit19","first-page":"227","article-title":"Prophylactic use of human Ig-GAM-preparations in patients on mechanical ventilation undergoing plasmapheresis: results of a randomized study","volume":"29","author":"Horstkotte","year":"1992","journal-title":"Intensivmedizin und Notfallmedizin"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1744-9987.1998.tb00124.x","article-title":"Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report","volume":"2","author":"Hosokawa","year":"1998","journal-title":"Therapeutic Apheresis"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1090-3798(97)80004-9","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barr\u00e9 syndrome","volume":"1","author":"Kanra","year":"1997","journal-title":"European Journal of Paediatric Neurology"},{"issue":"11","key":"10.1002\/14651858.CD002063.pub6-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/08830738030180110501","article-title":"Ten-year prospective study (clinical spectrum) of childhood Guillain-Barr\u00e9 syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras","volume":"18","author":"Koul","year":"2003","journal-title":"Journal of Child Neurology"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1097-4598(200101)24:1<54::AID-MUS6>3.0.CO;2-9","article-title":"Intravenous immunoglobulin therapy for Guillain-Barr\u00e9 syndrome","volume":"24","author":"Kuwabara","year":"2001","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1002\/14651858.CD002063.pub6-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF02229327","article-title":"High dose intravenous immune globulins and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"16","author":"Ravasio","year":"1995","journal-title":"Italian Journal of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0887-8994(96)00050-1","article-title":"Severe Guillain-Barr\u00e9 syndrome in childhood treated with human immune globulin","volume":"14","author":"Reisin","year":"1996","journal-title":"Paediatric Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0026|cit26","first-page":"166","article-title":"Treatment of Guillain-Barr\u00e9 syndrome: immunoglobulins or plasmapheresis","volume":"13","author":"Y\u00e9lamos","year":"1998","journal-title":"Neurologia"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1529-8027.2009.00215.x","article-title":"What's new in Guillain-Barr\u00e9 syndrome 2007-2008","volume":"14","author":"Doorn","year":"2009","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27 Suppl","author":"Asbury","year":"1990","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.53.2.409","article-title":"Residual physical outcome and daily living 3 to 6 years after Guillain-Barr\u00e9 syndrome","volume":"53","author":"Bernsen","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N","article-title":"Complications of intravenous gammaglobulin in neuromuscular and other diseases","volume":"19","author":"Bertorini","year":"1996","journal-title":"Muscle & Nerve"},{"issue":"1-2","key":"10.1002\/14651858.CD002063.pub6-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jneuroim.2013.01.001","article-title":"Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action?","volume":"256","author":"Bick","year":"2013","journal-title":"Journal of Neuroimmunology"},{"issue":"10","key":"10.1002\/14651858.CD002063.pub6-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1136\/jnnp.55.10.980-b","article-title":"Aseptic meningitis associated with high dose intravenous immunoglobulin therapy","volume":"55","author":"Casteels-van Daele","year":"1992","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD002063.pub6-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00002826-199510000-00001","article-title":"A comparison between IVIg and plasma exchange in Guillain-Barr\u00e9 syndrome: a review and decision analysis of the two treatment modalities","volume":"18","author":"Dawson","year":"1997","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0035|cit35","article-title":"33 Blood, blood components, plasma and plasma products","volume-title":"Side Effects of Drugs Annual","author":"Eijkhout","year":"2002"},{"issue":"9093","key":"10.1002\/14651858.CD002063.pub6-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","article-title":"Efficacy of a repeated intravenous immunoglobulin in severe unresponsive Guillain-Barr\u00e9 syndrome","volume":"350","author":"Farcas","year":"1997","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002063.pub6-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"Efficiency of plasma exchange in Guillain-Barr\u00e9 syndrome: role of replacement fluids","volume":"22","author":"French Co-operative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","year":"1987","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ana.410320115","article-title":"Plasma exchange in Guillan-Barr\u00e9 syndrome: one-year follow- up","volume":"32","author":"French Co-operative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","year":"1992","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome","volume":"41","author":"French Co-operative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","year":"1997","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD002063.pub6-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome","volume":"35","author":"The Guillain-Barr\u00e9 Syndrome Study Group","year":"1985","journal-title":"Neurology"},{"issue":"8382","key":"10.1002\/14651858.CD002063.pub6-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0140-6736(84)91341-2","article-title":"Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"1","author":"Greenwood","year":"1984","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD002063.pub6-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. The Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","volume":"44","author":"Hadden","year":"1998","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0043|cit43","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"8093","key":"10.1002\/14651858.CD002063.pub6-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial of prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"issue":"9497","key":"10.1002\/14651858.CD002063.pub6-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"issue":"Pt 9","key":"10.1002\/14651858.CD002063.pub6-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"issue":"8","key":"10.1002\/14651858.CD002063.pub6-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001446.pub4","article-title":"Corticosteroids for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8232","key":"10.1002\/14651858.CD002063.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"issue":"Pt 6","key":"10.1002\/14651858.CD002063.pub6-BIB0049|cit49","first-page":"2053","article-title":"The prognosis and main prognostic indicators of Guillain-Barr\u00e9 syndrome: a multicentre prospective study of 297 patients","volume":"119","author":"The Italian Guillain-Barr\u00e9 Group","year":"1996","journal-title":"Brain"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","article-title":"Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barr\u00e9 syndrome","volume":"40","author":"Jacobs","year":"1996","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD002063.pub6-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.38.10.1639","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with high dose gammaglobulin","volume":"38","author":"Kleyweg","year":"1988","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD002063.pub6-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mus.880141111","article-title":"Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome","volume":"14","author":"Kleyweg","year":"1991","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0053|cit53","article-title":"Blood, blood components, plasma and plasma products","volume-title":"Meyler's Side Effects of Drugs","author":"Koch","year":"2000"},{"issue":"5","key":"10.1002\/14651858.CD002063.pub6-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/jnnp.70.4.560","article-title":"Indicators of rapid clinical recovery in Guillain-Barr\u00e9 syndrome","volume":"70","author":"Kuwabara","year":"2001","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD002063.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/qjmed\/93.11.751","article-title":"Nephrotoxicity of intravenous immunoglobulin","volume":"93","author":"Levy","year":"2000","journal-title":"Quarterly Journal of Medicine"},{"issue":"9407","key":"10.1002\/14651858.CD002063.pub6-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"issue":"8719","key":"10.1002\/14651858.CD002063.pub6-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/0140-6736(90)92374-Q","article-title":"Anaphylaxis with intravenous gammaglobulin","volume":"336","author":"McCluskey","year":"1990","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD002063.pub6-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1212\/WNL.53.8.1648","article-title":"Fatigue in immune-mediated polyneuropathies","volume":"53","author":"Merkies","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<107::AID-JCA1>3.0.CO;2-3","article-title":"Treatment of Guillain-Barr\u00e9 syndrome: a cost-effectiveness analysis","volume":"14","author":"Nagpal","year":"1999","journal-title":"Journal of Clinical Apheresis"},{"issue":"23","key":"10.1002\/14651858.CD002063.pub6-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD002063.pub6-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1986.03380100107031","article-title":"The utility of therapeutic plasmapheresis for neurological disorders","volume":"256","author":"NIH Consensus Development","year":"1986","journal-title":"JAMA"},{"issue":"8415","key":"10.1002\/14651858.CD002063.pub6-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(84)90819-5","article-title":"Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"2","author":"Osterman","year":"1984","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD002063.pub6-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","article-title":"Outcome and its predictors in Guillain-Barre syndrome","volume":"83","author":"Rajabally","year":"2012","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD002063.pub6-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001798.pub2","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","author":"Raphael","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/jnnp.64.1.74","article-title":"Epidemiological study of Guillain-Barr\u00e9 syndrome in south east England","volume":"64","author":"Rees","year":"1998","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0067|cit67","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jns5.12020","article-title":"Update on Guillain-Barre syndrome","volume":"18","author":"Rinaldi","year":"2013","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD002063.pub6-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1002\/14651858.CD002063.pub6-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archneur.1993.00540020015010","article-title":"Acute renal failure resulting from intravenous immunoglobulin therapy","volume":"50","author":"Tan","year":"1993","journal-title":"Archives of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD002063.pub6-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jocn.2006.03.020","article-title":"Pharmacoeconomics of therapy for Guillain-Barr\u00e9 syndrome: plasma exchange and intravenous immunoglobulin","volume":"14","author":"Tsai","year":"2007","journal-title":"Journal of Clinical Neuroscience"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial","volume":"363","author":"Koningsveld","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD002063.pub6-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"Koningsveld","year":"2007","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002063.pub6-BIB0076|cit76","first-page":"337","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"Nes","year":"2011","journal-title":"Clinical & Vaccine Immunology: CVI"},{"issue":"Pt 5","key":"10.1002\/14651858.CD002063.pub6-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/brain\/awr318","article-title":"Modifying the Medical Research Council grading system through Rasch analyses","volume":"135","author":"Vanhoutte","year":"2012","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(85)90173-X","article-title":"Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy","volume":"70","author":"Vermeulen","year":"1985","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2133.1997.tb03773.x","article-title":"Eczematous reactions to human immune globulin","volume":"137","author":"Whittam","year":"1997","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD002063.pub6-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Services Research"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002063.pub6-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C","article-title":"Clinical features and response to treatment in Guillain-Barr\u00e9 syndrome associated with antibodies to GM1b ganglioside","volume":"47","author":"Yuki","year":"2000","journal-title":"Annals of Neurology"},{"issue":"24","key":"10.1002\/14651858.CD002063.pub6-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"unknown","key":"10.1002\/14651858.CD002063.pub6-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub2","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002063.pub6-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub3","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD002063.pub6-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub4","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD002063.pub6-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub5","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002063.pub6\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T02:32:47Z","timestamp":1740450767000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002063.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":88,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002063.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]}}}